Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
NVL-330 features among the latest crop of industry projects newly into human trials.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.